By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SQI Diagnostics today said that it has established a special committee to review strategic alternatives for the firm, which could include a possible merger or sale.

SQI said that the special committee was formed to "review interest from a number of parties relating to a possible merger or sale of the company." It also said that it will continue to explore other alternatives, such as strategic alliances.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.